首页 | 本学科首页   官方微博 | 高级检索  
     

Protective effects of erythropoietin pretreatment on myocardium with hypoxia/reoxygenation injury in rats
引用本文:秦川 肖颖彬 钟前进 陈林 王学锋. Protective effects of erythropoietin pretreatment on myocardium with hypoxia/reoxygenation injury in rats[J]. 中国人民解放军军医大学学报, 2004, 19(6): 329-332
作者姓名:秦川 肖颖彬 钟前进 陈林 王学锋
作者单位:DepartmentofCardiovascularSurgery,XingqiaoHospital,ThirdMilitaryMedicalUniversity,Chongqing400037,China
摘    要:
To establish the rat model with myocardial hypoxia/reoxygenation (H/R) injury, and investigate the protective effect of EPO pretreatment on the myocardium. Methods: Sixty male adult Wistar rats were randondv divided into 3 groups: control group, H/R group, and EPO group, 20 in each group. The rats in EPO group accepted injection of 5000 U/kg recombinant human erythropoietin (RHuEPO) through vein, and the other rats accepted the injection of the same volume of saline. Twenty-four hours after the injection, rats in the EPO and H/R groups were put into the hypoxia environment for 12h and then returned to the nonnoxic environment for 2 h, and then the samples of blood and myocardium were collected. Serum myocardial enzyme activity, apoptosis, ultrastructure, myocardial MDA contents, EPO receptor (EPOR) expression in cardiac myocytes and cardiac functions were tested. Results: EPOR expression was positive in cardiac myocytes of adult rat according to the result of immunohistochemitry assayng. Compared to those in H/R group, rats in EPO group presented lighter injury of myocardial ultrastructure, the reduction of serum myocardial erzyme activity, inhibition of apoptosis, the better recovery of cardiac functions, and the less production of oxygen-derived free radicals. Conclusion: Adult rat cardiac myocytes could express EPOR, and EPO pretreatment produced protective effects on myocardium with H/R injury.

关 键 词:保护作用 促红细胞生成素 预处理 心肌 复氧 组织缺氧 老鼠

Protective effects of erythropoietin pretreatment on myocardium with hypoxia/reoxygenation injury in rats
OIN Chuan XIAO Ying-bin ZHONG Oian-jin CHEN Lin WANG Xue-feng. Protective effects of erythropoietin pretreatment on myocardium with hypoxia/reoxygenation injury in rats[J]. Journal of Medical Colleges of PLA(China), 2004, 19(6): 329-332
Authors:OIN Chuan XIAO Ying-bin ZHONG Oian-jin CHEN Lin WANG Xue-feng
Affiliation:OIN Chuan XIAO Ying-bin ZHONG Oian-jin CHEN Lin WANG Xue-feng Department of Cardiovascular Surgery,Xingqiao Hospital,Third Military Medical University,Chongqing 400037,China
Abstract:
Objective: To establish the rat model with myocardial hypoxia/reoxygenation (H/R) injury, and investigate the protective effect of EPO pretreatment on the myocardium. Methods: Sixty male adult Wistar rats were randomly divided into 3 groups: control group, H/R group, and EPO group, 20 in each group. The rats in EPO group accepted injection of 5 000 U/kg recombinant human erythropoietin (RHuEPO) through vein, and the other rats accepted the injection of the same volume of saline. Twenty-four hours after the injection, rats in the EPO and H/R groups were put into the hypoxia environment for 12 h and then returned to the normoxic environment for 2 h, and then the samples of blood and myocardium were collected. Serum myocardial enzyme activity, apoptosis, ultrastructure, myocardial MDA contents, EPO receptor (EPOR) expression in cardiac myocytes and cardiac functions were tested. Results: EPOR expression was positive in cardiac myocytes of adult rat according to the result of immunonistochemitry assaying. Compared to those in H/R group, rats in EPO group presented lighter injury of myocardial ultrastructure, the reduction of serum myocardial enzyme activity, inhibition of apoptosis, the better recovery of cardiac functions, and the less production of oxygen-derived free radicals. Conclusion: Adult rat cardiac myocytes could express EPOR, and EPO pretreatment produced protective effects on myocardium with H/R injury.
Keywords:erythropoietin  myocardium  hypoxia/reoxygenation injury
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号